Voyager Acquisition Corp. (VACH)
| Market Cap | 67.92M -79.1% |
| Revenue (ttm) | n/a |
| Net Income | 6.74M +1.7% |
| EPS | 0.22 -24.8% |
| Shares Out | 6.41M |
| PE Ratio | 47.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,279 |
| Open | 10.60 |
| Previous Close | 10.60 |
| Day's Range | 10.60 - 10.60 |
| 52-Week Range | 8.40 - 15.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VACH
Voyager Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the healthcare or healthcare related sectors. Voyager Acquisition Corp. was incorporated in 2023 and is based in Brooklyn, New York.
News
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech AG has strengthened its financial position to position to support the closing of its business combination with Voyager Acquisition Corp.
Voyager Acquisition Corp trading resumes
09:37 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
09:32 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading halted, volatility trading pause
13:55 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading resumes
14:00 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
14:28 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading resumes
14:33 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
11:07 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading resumes
11:12 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading resumes
13:07 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
13:02 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading resumes
09:49 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
09:44 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corp trading resumes
09:37 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
09:32 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition 22M unit IPO priced at $10.00
Cantor is sole book-running manager.
Voyager Acquisition announces approval of combination with Veraxa Biotech
Voyager Acquisition (VACH) held the general meeting on March 12 and approved the previously announced business combination with Veraxa Biotech. After the closing of the Business Combination, it is exp...
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) held the general meeting on March 12, 2026 and approv...
Voyager Acquisition Corp trading resumes
09:57 EDT Voyager Acquisition (VACH) Corp trading resumes
Voyager Acquisition Corp trading halted, volatility trading pause
09:52 EDT Voyager Acquisition (VACH) Corp trading halted, volatility trading pause
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Com...
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
Partnership combines Secarna's OligoCreator® platform with VERAXA's technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases Partnership combines Secarna'...
Voyager Acquisition, VERAXA announce filing of Form F-4 registration statement
VERAXA Biotech and Voyager Acquisition (VACH) Corp. announced today the filing of a registration statement on Form F-4, which includes a preliminary proxy statement, with the U.S. Securities and Excha...
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempt...